Pack size: Box of 20 Tablets  |  Price is for the whole Box

⚠ Prescription required. This medicine may only be dispensed against a valid prescription.

Generic: Daprodustat

Form: tablet 2mg

Indication

_NAME_ is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. _NAME_ is not indicated for use: As a substitute for red blood cell transfusions in patients who require immediate correction of anemia. For treatment of anemia of chronic kidney disease in patients who are not on dialysis.

Administration

_NAME_ is available in 1,2,4,6 and 8-mg tablet formulations administered orally once daily, with or without food.

Adult Dose

$4b

Child Dose

Not recommended for children.

Renal Dose

Steady-state exposure of _NAME_ is similar in patients with normal renal function and those with varying degrees of renal impairment Hemodialysis or peritoneal dialysis _NAME_ exposure not significantly impacted Systemic exposure of _NAME_ metabolites was higher in patients with Stage 3-5 CKD than in those with normal renal function. Exposures of metabolites were higher on non-dialysis days than on dialysis days.

Contraindication

Receiving a strong CYP2C8 inhibitor such as gemfibrozil. With uncontrolled hypertension.

Introduction

_NAME_ is a hypoxia-inducible factor, prolyl hydroxylase inhibitor (HIF-PHI). The activity of HIF-PH enzymes controls intracellular levels of HIF, a transcription factor that regulates the expression of genes involved in erythropoiesis. Activation of the HIF pathway is important in the adaptive response to hypoxia to increase red blood cell production. Through the reversible inhibition of HIF-PH, Daprodustat stimulates a coordinated erythropoietic response that includes the increase of plasma endogenous erythropoietin (EPO) levels, regulation of iron transporter proteins and reduction of hepcidin (an iron regulator protein that is increased during inflammation in CKD). This results in improved iron bioavailability, increased Hb production and increased red cell mass.

Uses of __NAME__

__NAME__ is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. __NAME__ is not indicated for use: As a substitute for red blood cell transfusions in patients who require immediate correction of anemia. For treatment of anemia of chronic kidney disease in patients who are not on dialysis.

Side effects of __NAME__

Risk of hospitalization due to heart failure High blood pressure damage to the lining of the stomach, the tube that connects the mouth and stomach (esophagus), and intestines (gastrointestinal erosion).

How to use __NAME__

__NAME__ is to be taken orally.Take this medicine in the dose and duration as advised by your doctor. Do not chew, crush or break it.

How __NAME__ works

_NAME_ is a hypoxia-inducible factor, prolyl hydroxylase inhibitor (HIF-PHI). The activity of HIF-PH enzymes controls intracellular levels of HIF, a transcription factor that regulates the expression of genes involved in erythropoiesis. Activation of the HIF pathway is important in the adaptive response to hypoxia to increase red blood cell production. Through the reversible inhibition of HIF-PH, Daprodustat stimulates a coordinated erythropoietic response that includes the increase of plasma endogenous erythropoietin (EPO) levels, regulation of iron transporter proteins and reduction of hepcidin (an iron regulator protein that is increased during inflammation in CKD). This results in improved iron bioavailability, increased Hb production and increased red cell mass.

What if you forget to take __NAME__?

If you miss a dose of _NAME_ Tablet, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.

Safety Advice

Caution is advised when consuming alcohol with __NAME__. Please consult your doctor.

Safety Advice

May cause fetal harm

Safety Advice

Breastfeeding not recommended until one week after the final dose.

Safety Advice

It is not known whether __NAME__ alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.

Safety Advice

__NAME__ is safe to use in patients with kidney disease. No dose adjustment of __NAME__ is recommended.

Safety Advice

__NAME__ should be used with caution in patients with severe liver disease. Dose adjustment of __NAME__ may be needed. Please consult your doctor. A lower dose may be advised in patients with liver disease and who have to take this medicine for a long time.